Overall market sentiment has been down on Minerva Neurosciences Inc (NERV) stock lately. NERV receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Minerva Neurosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NERV!
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With NERV Stock Today?
Minerva Neurosciences Inc (NERV) stock is trading at $3.40 as of 1:18 PM on Thursday, Aug 18, a gain of $0.11, or 3.34% from the previous closing price of $3.29. The stock has traded between $3.25 and $3.67 so far today. Volume today is low. So far 402,512 shares have traded compared to average volume of 1,429,986 shares.
To see InvestorsObserver's Sentiment Score for Minerva Neurosciences Inc click here.
More About Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and
commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include
schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone
for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive
disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Click Here to get the full Stock Report for Minerva Neurosciences Inc stock.